Background: Regular binge drinking is associated with numerous adverse consequences yet the U.S. Food and Drug Administration (FDA) has approved only 4 medications for the treatment of alcohol use disorders (AUDs), and none have been specifically targeted for treating binge drinking. Here we assessed the effectiveness of the dopamine/norepinephrine reuptake inhibitor, bupropion (BUP), alone and in combination with naltrexone (NAL), to reduce binge-like and chronic ethanol intake in mice. While BUP is an FDA-approved drug that is currently used to treat depression and nicotine dependence there has been only limited investigation to assess the ability of BUP to reduce ethanol intake. Methods: Male C57BL/6J mice were tested with 20% (v/v) ethanol using "drinking in the dark" (DID) procedures to model binge-like ethanol intake and following intermittent access to ethanol (IAE). In Experiment 1, mice were given intraperitoneal (i.p.) injection of 0, 20, or 40 mg/kg BUP 30-min before DID testing, in Experiment 2 mice were given i.p. injection of vehicle, BUP (20 mg/kg), NAL (3 mg/kg), or BUP + NAL (20 and 3 mg/kg, respectively) 30 min before DID testing, and in Experiment 3 mice were given i.p. injection of 0, 20, 40 or 60 mg/kg BUP 30-min before ethanol access after mice had 16-weeks of IAE. Results: BUP dose-dependently blunted ethanol intake with DID procedures and after 16-weeks of IAE. Administration of subthreshold doses of BUP + NAL also reduced binge-like ethanol intake. Finally, BUP failed to reduce consumption of a 3% (w/v) sucrose solution.